3 results
Primary objective: To evaluate the effect of navitoclax in combination with ruxolitinib on splenomegaly response when compared to ruxolitinib in subjects with myelofibrosis.Secondary objectives:• To evaluate the effect of navitoclax in combination…
We aim to assess whether risk modification effectiveness is visible on follow-up CT and in biomarker values when comparing baseline with 12 months follow-up in patients without significant obstructive coronary artery disease on coronary Ct. We also…
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and pertuzumab as maintenance therapy in subjects with advanced HER2+ breast cancer who have had prior treatment with a taxane, trastuzumab, and pertuzumab.